What the FDA labels say about taking them together
Afatinib and cyclosporine
Afatinib's FDA label of November 13, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name afatinib. The afatinib label: “Increase GILOTRIF by 10 mg per day as tolerated. Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors with GILOTRIF can increase exposure to afatinib.”
Check it at the source: the afatinib FDA label on DailyMed (effective November 13, 2025, Boehringer Ingelheim Pharmaceuticals, Inc.); the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation).
What does the afatinib label say about cyclosporine?
Afatinib label, drug interactionsIncrease GILOTRIF by 10 mg per day as tolerated. ( 2.5 , 7 ) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Gilotrif), Boehringer Ingelheim Pharmaceuticals, Inc., effective November 13, 2025 (SPL set fd638e5e-8032-e7ca-0179-95e96ab5d387), via openFDA; the full label on DailyMed
What does the cyclosporine label say about afatinib?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name afatinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Afatinib | Cyclosporine | |
|---|---|---|
| Labeled for | Lung cancer | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $1.04 per unit 0.05% eye emulsion |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once